X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

Rejected By The FDA, NICE Endorses The Anaemia Drug Evrenzo

Content Team by Content Team
11th June 2022
in FDA Approvals, News

Despite a high-profile FDA denial, FibroGen and its collaborators have been able to expand into new markets outside of the United States with Evrenzo, a novel oral anaemia medication. Evrenzo, also called Roxadustat, has been approved for reimbursement in England to treat some individuals with symptomatic anaemia caused by chronic renal disease. In Europe, Evrenzo’s rights are held by Astellas.

The National Institute for Health and Care Excellence (NICE) coverage decision is a strong endorsement of roxadustat as a cost-effective oral treatment option, according to Timir Patel, medical director at Astellas UK & Ireland. The NICE suggestion has some caveats, which Astellas claims are in keeping with Evrenzo’s local marketing permission. Patients with phase 3 to 5 chronic kidney disease who do not have an iron shortage and are not on dialysis are not eligible for Evrenzo.

NICE indicated in its assessment that Evrenzo can be seen as an alternative to injectable erythropoiesis-stimulating drugs. Many people with anaemia find administering themselves uncomfortable and challenging, according to NICE reviewers. As a result, the evaluators concluded that these individuals would benefit from oral therapy. Evrenzo is the first oral HIF-PH inhibitor to receive FDA approval in any country.

More crucially, Astellas provided a discreet discount to make the medicine a cost-effective use of NHS resources. Evrenzo is available in 12-tablet packets from Astellas in five different dosage formats. The cheapest dose, 20-mg tablets, costs 59.24 pounds ($74.3) on the list. The most expensive dosage, 150 mg, has a list price of 444.32 pounds (557.27). The savings offered by Astellas are not reflected in those prices.

Evrenzo was tested in four randomised clinical trials by FibroGen and collaborators in CKD anaemia individuals who were not on dialysis. NICE, on the other hand, only looked at one trial, called Dolomites, since the others compared Evrenzo to a placebo. In the Dolomites, Evrenzo showed it could achieve and maintain target haemoglobin levels as well as Amgen’s ESA treatment Aranesp. Additionally, the new medicine proved more effective at minimising the need for iron injections.

In late 2018, Evrenzo received first-in-class approval in China, thanks to a collaboration between FibroGen and AstraZeneca. It appeared to be on track to be the first on the market in the United States at the time. Last year, however, the FDA denied the drug, citing concerns about its toxicity profile, particularly some heart disease risks, including thrombosis and deaths. AZ and FibroGen are still at odds as to whether or how to perform a fresh clinical trial that could lead to a resubmission to the FDA.

In the meantime, European officials remain unconcerned about the drug’s adverse effects. Last year, the European Commission approved the medicine for symptomatic anaemia associated with CKD, and the Medicines and Healthcare Products Regulatory Agency in the United Kingdom immediately followed suit.

Previous Post

Time Congress Acts As Drug Launch Prices Go Up 20% Annually

Next Post

After Lupin Deal Teva Holds Another Austedo Rival To 2033

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post

After Lupin Deal Teva Holds Another Austedo Rival To 2033

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In